Dipen M Maru

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 32:1404-11. 2008
  2. ncbi request reprint Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 34:1287-94. 2010
  3. doi request reprint Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1576-85. 2009
  4. doi request reprint Barrett's esophagus: diagnostic challenges and recent developments
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Diagn Pathol 13:212-21. 2009
  5. doi request reprint Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance
    Roopma Wadhwa
    Department of GI Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Tex, USA
    Oncology 85:204-7. 2013
  6. pmc A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer
    Yuki Hayashi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Eur J Cancer 48:3396-404. 2012
  7. ncbi request reprint The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma
    Ashleigh M Francis
    Departments of Thoracic and Cardiovascular Surgery, GI Medical Oncology, Diagnostic Radiology, GI Medicine and Nutrition, Pathology, Radiation Therapy, and Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:500-7. 2013
  8. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
  9. pmc Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012
  10. pmc Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation
    Takashi Taketa
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology 83:300-4. 2012

Detail Information

Publications42

  1. ncbi request reprint Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 32:1404-11. 2008
    ..031). There was no difference in prognosis between patients with large-cell NEC and those with small-cell neuroendocrine carcinoma. Esophageal NEC is an aggressive tumor, and patients with mix NEC have better outcome...
  2. ncbi request reprint Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 34:1287-94. 2010
    ....
  3. doi request reprint Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1576-85. 2009
    ..It was unclear whether this difference was due to loss of heterozygosity (LOH) or to other genetic alterations at this locus...
  4. doi request reprint Barrett's esophagus: diagnostic challenges and recent developments
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Diagn Pathol 13:212-21. 2009
    ..All nonhistologic markers are still in the investigational phase and have not yet been validated in phase 3/4 prospective trials...
  5. doi request reprint Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance
    Roopma Wadhwa
    Department of GI Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Tex, USA
    Oncology 85:204-7. 2013
    ..It is unclear whether patients undergoing trimodality therapy (TMT) should be screened or surveyed for brain metastases...
  6. pmc A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer
    Yuki Hayashi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Eur J Cancer 48:3396-404. 2012
    ..Currently, none of the clinical variables highly correlates with +ypNodes. We hypothesised that a combination of clinical variables could generate a model that associates with high likelihood of +ypNodes after trimodality in EC patients...
  7. ncbi request reprint The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma
    Ashleigh M Francis
    Departments of Thoracic and Cardiovascular Surgery, GI Medical Oncology, Diagnostic Radiology, GI Medicine and Nutrition, Pathology, Radiation Therapy, and Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:500-7. 2013
    ..Our aim was to validate the effect of histopathologic tumor viability (HTV) on extended survival outcomes and assess the prognostic ability of the current staging system in patients receiving preoperative chemoradiotherapy (CRT)...
  8. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
    ..The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer...
  9. pmc Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012
    ....
  10. pmc Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation
    Takashi Taketa
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology 83:300-4. 2012
    ..The literature on the outcome of such patients is sparse...
  11. pmc Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1079-88. 2013
    ..To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy...
  12. pmc Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:642-50. 2012
    ..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)...
  13. pmc Does the timing of esophagectomy after chemoradiation affect outcome?
    Jae Y Kim
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Ann Thorac Surg 93:207-12; discussion 212-3. 2012
    ..However, there are theoretical concerns that waiting longer after radiation may lead to a more difficult operation and more complications. The optimal timing of esophagectomy after CXRT is unknown...
  14. pmc Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
    Yun Shin Chun
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    JAMA 302:2338-44. 2009
    ....
  15. pmc RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
    Jean Nicolas Vauthey
    Departments of Surgical Oncology Gastrointestinal Medical Oncology Hematopathology Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:619-26; discussion 626-7. 2013
    ..To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy...
  16. doi request reprint Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma
    Jeannelyn S Estrella
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Am J Surg Pathol 35:1045-53. 2011
    ..EAC invasion into the space between duplicated MM confers a similar risk of lymph node metastasis and recurrence as those of intramucosal EAC, and LVI is the best predictor of lymph node status and RFS in pT1 EAC...
  17. pmc Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma
    Chiaojung Jillian Tsai
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:3713-22. 2011
    ....
  18. pmc Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4484-92. 2011
    ..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown...
  19. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  20. ncbi request reprint Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma
    Mahmoud Goodarzi
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 22:1612-21. 2009
    ..In addition, phosphorylated histone H3 is a potential supportive marker to histology in differentiating low-grade dysplasia from indefinite for dysplasia and high-grade dysplasia from adenocarcinoma in the mucosal biopsy samples...
  21. doi request reprint Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation
    Takashi Taketa
    The University of Texas M D Anderson Cancer Center, Houston, TX 70030, USA
    Oncology 85:95-9. 2013
    ....
  22. doi request reprint Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2870-6. 2010
    ..We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM...
  23. pmc Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience
    Panteleimon Kountourakis
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:925-30. 2011
    ..This study analyzed the largest series of consecutive cT2N0M0 esophageal cancer patients treated with preoperative chemoradiotherapy...
  24. pmc Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma
    Shumei Song
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:2159-69. 2013
    ..Taken together, our findings suggest that loss of β2SP switches TGF-β signaling from tumor suppression to tumor promotion by engaging Notch signaling and activating SOX9...
  25. ncbi request reprint Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status
    Min P Kim
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 90:884-90; discussion 890-1. 2010
    ..We hypothesized that these patients would have similar survival to patients with incomplete response to therapy...
  26. ncbi request reprint Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:1656-63. 2010
    ..It was hypothesized that chemoradiotherapy with fluoropyrimidine, taxane, and camptothecin would have preserved or improved efficacy with no compromise in safety...
  27. ncbi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
    ..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia...
  28. ncbi request reprint Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma
    Takashi Taketa
    From the Departments of Gastrointestinal Medical Oncology Thoracic and Cardiovascular Surgery Internal Medicine Radiation Oncology Gastroenterology, Hepatology, and Nutrition and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Natl Compr Canc Netw 12:1139-44. 2014
    ..Thus, the surveillance strategy can potentially be customized based on SPS. These data can inform a future evidence-based surveillance strategy that can be efficient and cost-effective. ..
  29. ncbi request reprint Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy
    Atin Agarwal
    Department of Pathology, Baylor College of Medicine, Houston, Texas
    Cancer 119:4231-41. 2013
    ..The current study was conducted to determine whether quantified pathologic response assessed as a percentage of residual tumor cells is predictive of recurrence-free survival (RFS) in patients with rectal cancer...
  30. doi request reprint Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy
    Akihiro Suzuki
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:108-13. 2012
    ..We used a number of clinical pre- and post-treatment parameters to establish two nomograms: for overall survival (OS) and relapse-free survival (RFS)...
  31. ncbi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...
  32. doi request reprint CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab
    Piyaporn Boonsirikamchai
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    AJR Am J Roentgenol 197:W1060-6. 2011
    ..We also discuss the respective value of these criteria and the Response Evaluation Criteria in Solid Tumors (RECIST)...
  33. pmc Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties
    Shumei Song
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 74:4170-82. 2014
    ..Cancer Res; 74(15); 4170-82. ©2014 AACR. ..
  34. pmc Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer
    Hironori Shiozaki
    U T M D Anderson Cancer Center, Houston, Tex, USA
    Oncology 86:336-9. 2014
    ..Distant metastases (DMs) are common but the details of their distribution and timing in a large cohort have not been described...
  35. doi request reprint Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma
    William D Bolton
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Cardiovasc Surg 138:831-6. 2009
    ..The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well evaluated...
  36. pmc Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy
    Akihiro Suzuki
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4823-33. 2011
    ..The authors hypothesized that initial SUV would correlate with patient outcome...
  37. doi request reprint Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:824-30. 2010
    ..We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer...
  38. pmc Vital-dye enhanced fluorescence imaging of GI mucosa: metaplasia, neoplasia, inflammation
    Nadhi Thekkek
    Department of Bioengineering, Rice University, Houston, Texas 77005, USA
    Gastrointest Endosc 75:877-87. 2012
    ..Multiscale endoscopy platforms that use widefield imaging are needed to better direct the placement of high-resolution probes...
  39. pmc MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Am J Pathol 174:1940-8. 2009
    ..In conclusion, this study identified miR-196a as a potential marker of progression of BE and KRT5, SPRR2C, and S100A9 as its targets...
  40. doi request reprint Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer
    Motofumi Tanaka
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:4531-40. 2011
    ..This study was designed to determine whether DNA methylation biomarkers are associated with recurrence and survival in colon cancer patients...
  41. pmc Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1
    Jia Lu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 23:171-85. 2013
    ..Collectively, ECs play an active role in promoting Notch signaling and the CSC phenotype by secreting soluble Jagged-1...
  42. pmc Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo
    Parmeswaran Diagaradjane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    ACS Nano 4:4131-41. 2010
    ..This pretreatment strategy could have broad applicability across biomedical applications utilizing theranostic nanoparticles that are sequestered by the RES...